Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

Author(s):
Biemans, V.B.C.; Woude, C.J. van der; Dijkstra, G.; Meulen-de Jong, A.E. van der; Oldenburg, B.; Boer, N.K. de; Lowenberg, M.; Srivastava, N.; Bodelier, A.G.L.; West, R.L.; Jansen, J.M.; Vries, A.C. de; Haans, J.J.L.; Jong, D.J. de; Pierik, M.J.; Hoentjen, F.; Dutch Initiative Crohn Colitis
Published
2019
Publication type
Article / Letter to editor
Date issued
2019-12-11
Language
English
Is part of
Clinical Pharmacology and Therapeutics
hdl
1887/121015
doi
10.1002/cpt.1712